Non-Opioid Pain Treatment Market: A Comprehensive Research Report


Posted January 2, 2024 by delvens123

The global Non-opioid Pain Treatment Market size is projected to reach a CAGR of 7.1% from 2023-2030.

 
Non-opioid Pain Treatment Market by Drug Class (NSAIDs, Acetaminophen, Local Anaesthetics), By Pain Type, By Route of Administration, By Distribution Channel, and by region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Non-Opioid Pain Treatment Market Overview
The global Non-opioid Pain Treatment Market size is projected to reach a CAGR of 7.1% from 2023-2030.
Non-opioid pain relievers are a form of pain reliever that has been specifically created to manage mild to moderate pain. They're commonly used to treat neuropathic pain, cancer pain, orthopaedic and musculoskeletal pain, and other conditions. Medical cannabis, botulinum toxins, capsaicin derivatives, and other non-opioid pain treatments are among the most common.
The rising global prevalence of osteoarthritis, fuelled by the ageing population, joint injuries, obesity, repeated stress on the joint, genetics, metabolic illnesses, and bone abnormalities, is expected to fuel demand for non-opioid pain treatment patches. The rising prevalence of chronic pain in India is expected to push the non-opioid pain patch market in South Asia. The market is expected to benefit from the government's increasing investments in the construction of a well-established healthcare infrastructure to treat pain-related disorders. Another important factor expected to boost the market is the growing demand for non-opioid pain management patches due to their ability to reduce the risk of addiction when compared to fentanyl patches when released over a lengthy period of time. In the foreseeable future, the rising demand for minimally invasive therapies is likely to boost growth
On the other hand, factors such as the high cost of patent drugs and the use of opioids in various underdeveloped and developing countries will hinder the non-opioid pain treatment market.
Get a Sample Copy of the Non-Opioid Pain Treatment Market Research Report: https://www.delvens.com/get-free-sample/non-opiod-pain-treatment-market
Due to the spread of COVID-19, the clinic's services were severely impacted by the nationwide lockdown and continued rise in infection rates across the country. Many pain and clinic services have seen a decrease in patient visits as a result of COVID-19, resulting in less client engagement. During COVID-19, several clinics and pain services saw a drop in the number of visits.
Delvens Industry Expert's Standpoint
The growing incidence of chronic pain is due to the prevalence of server pain-causing conditions such as arthritis, cancer pain, and neuropathic pain. This created a demand for effective pain management solutions, where consumers looking for non-invasive and non-pharmacological methods to treat these kinds of pain that open up opportunities for non-opioid pain treatments. Further, the consumers are aware of the side effects and risks associated with opioid-based treatment which drives them to make use of non-opioid-based pain interventions. Moreover, the enhancement in alternative treatments such as nerve blockers, cannabinoids, alternative therapies like acupuncture and physical therapy, and government awareness programs on reducing opioid drug abuse continues to grow the market of non-opioid pain treatment in the next coming years.
Key Findings
• The drug class segment is further fragmented into NSAIDs, Acetaminophen, Local Anaesthetics and Others. The nonsteroidal anti-inflammatory drugs (NSAIDs) segment dominated the industry and accounted for the largest revenue share. The growth of the segment is due to the wide availability of effective NSAID medications with low costs and safer alternatives to opioids for treatment. Some of the NSAIDs that are globally used include Cambia, Cataflam, Dyloject, Zipsor, Zorvolex, Advil, Motrin, and Aleve, among others.
• The pain type segment is further fragmented into Chronic Pain, Post-operative Pain, Cancer Pain and Others. The chronic pain segment dominated the market with the largest revenue share. The growth of the segment is due to the increasing prevalence of chronic pain such as neuropathic pain and pain associated with inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and others coupled with increased demand for non-opioid analgesic drugs.
• The route of administration segment is further fragmented into Oral, Injectable, Topical and Others. The oral segment dominated the non-opioid analgesics market and accounted for the largest revenue share. The growth of the segment is due to the approval and launch of new oral NSAIDs for pain management. Key oral non-opioid analgesics drug prescribed by physicians to their patients for pain management includes Celebrex (celecoxib), Cambia, Cataflam, Dyloject, Zipsor, and Zorvolex (diclofenac potassium), Anaprox, Anaprox Ds, Ec-Naprosyn, Naprosyn, Naprelan, and Treximet (naproxen sodium), Lodine (etodolac), Nalfon (fenoprofen), Motrin & Advil (ibuprofen), and Daypro (oxaprozin), among others. Advil is available in tablet formulation and administered orally to relieve pain from various conditions such as muscle aches, dental pain, headache, and menstrual cramps.
• The distribution channel segment is further fragmented into Hospital Pharmacy, Retail Pharmacy and Others. The retail pharmacy segment dominated the non-opioid pain treatment market and accounted for the largest revenue share. The growth is majorly due to the wide availability of non-opioid analgesic drugs and easy accessibility to medicines for patients.
• The market is also segmented into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is the fastest-growing market for non-opioid pain treatment market. It holds a revenue share of 39.5% for this market in 2022. The increase in clinical trials and funding by the government drives the growth of this market in the North America region.
Non-Opioid Pain Treatment Market Regional Analysis
North America to Dominate the Market
• North America dominated the non-opioid pain treatment industry and accounted for the largest revenue share.
• This dominance can be attributed to the high demand for NSAIDs, proactive government measures for limiting opioid use, improvements in healthcare infrastructure, and the presence of major players. Favourable government initiatives and reimbursement policies are likely to drive market growth.
Non-Opioid Pain Treatment Market Competitive Landscape
• Novartis AG
• Teva Pharmaceutical Industries Limited
• Dr. Reddy’s Laboratories Ltd
• Sun Pharmaceutical Industries Ltd
• GSK plc.
• Pfizer Inc.
• Perrigo Company plc
• LNK International, Inc.
• Cipla Inc.
• Johnson & Johnson Services, Inc.
• Pacira Pharmaceuticals, Inc.
• Pierrel
• Eli Lilly and company (U.S.)
• Regeneron Pharmaceuticals Inc.
• Centrexion Therapeutics Corp.
• Acorda Therapeutics
• Biogen
• VM Biotech
• Alder Biopharmaceuticals
• Veridian Healthcare
Inquire before you purchase to increase your business' revenue: https://www.delvens.com/Inquire-before-buying/non-opiod-pain-treatment-market
Non-Opioid Pain Treatment Market Recent Developments
• In January 2021, a Duke-led team of scientists developed a biocompatible surgical patch that delivers non-opioid medicines to the wound site for days before dissolving. The novel polymer patch administers a regulated release of a medication that blocks the enzyme COX-2 (cyclooxygenase-2,) which is responsible for inflammation and pain.
• In May 2022, Hisamitsu America Celebrates Salonpas Day with Free Patch Offer from Doctor Recommended OTC Pain Relief Patch Brand. Salonpas was named the number-one doctor-recommended brand of pain relief patches in the United States in 2021
• In February 2022, NEXGEL, Inc., a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, reported the launch of its MEDAGEL Bug Bite Relief Patch. These cooling patches, made in the USA using NEXGEL's soothing hydrogel technology, provide instant relief to irritated skin caused by insect bites.
Reasons to Acquire in the Non-Opioid Pain Treatment Market
• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors.
• Gain authentic and granular data access for Non-opioid Pain Treatment Market so as to understand the trends and the factors involved behind changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Direct Purchase of Non-Opioid Pain Treatment Market Report Research Report: https://www.delvens.com/checkout/non-opiod-pain-treatment-market
Frequently Asked Questions
What are the years considered to study Non-opioid Pain Treatment Market intelligence report?
What is the compound annual growth rate (CAGR) of the Non-opioid Pain Treatment Market?
Which region holds the largest market share in Non-opioid Pain Treatment Market?
Which region holds the largest market share in Non-opioid Pain Treatment Market?
Who are the major players in Non-opioid Pain Treatment Market?
Browse Related Reports:
Vascular Imaging Market – Trends Forecast Till 2030
Vascular Imaging Market by Technique (Magnetic Resonance Imaging, Ultrasound, Computed Tomography, Nuclear Imaging, X-Ray), by Procedure (Coronary Angiography, Peripheral Angiography, Neurovascular Angiography, Vascular Ultrasound Procedures, Micro Angiography, Other Procedures) and by End User (Hospitals, Diagnostic Imaging Centers, Other End Users) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Blood Banking Devices Market – Trends Forecast Till 2030
Blood Banking Devices Market, by Product (Blood Collection Devices, Blood Processing Devices, Blood Storage Devices), End- Users (Hospital, Academic Institutes, Independent Diagnostics Centers/Clinics, Blood Banks), Mode of Collection (Manual Blood Collection, Automated Blood Collection) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
Diagnostic Imaging Services Market – Trends Forecast Till 2030
Diagnostic Imaging Services Market, By Procedure (Computed Tomography, MRI, and X-ray), By Application (Neurology, Oncology, and Cardiology), By Service Provider (Diagnostic Centres, Hospitals, Ambulatory Surgical Centers, and Others), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
[email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Delvens
Country China
Categories Business , Health
Last Updated January 2, 2024